Aquestive Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary

• Aquestive Therapeutics Inc AQST.OQ reported a quarterly adjusted loss of 14 cents​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of -3 cents. The mean expectation of nine analysts for the quarter was for a loss of 17 cents per share. Wall Street expected results to range from -22 cents to -14 cents per share.

• Revenue fell 50.2% to $10.00 million from a year ago; analysts expected $11.32 million.

• Aquestive Therapeutics Inc's reported EPS for the quarter was a loss of 14 cents​.

• The company reported a quarterly loss of $13.55 million.

• Aquestive Therapeutics Inc shares had risen by 17.8% this quarter and gained 9.6% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 5.2% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the pharmaceuticals peer group is also "buy"

• Wall Street's median 12-month price target for Aquestive Therapeutics Inc is $8.00, about 51.2% above its last closing price of $3.90

This summary was machine generated from LSEG data August 11 at 09:01 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)